Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Oh, yep
Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long
IM Injection: Dosages are usually lower and adjusted based on the specific health goals and medical advice
The safety of ingested caffeine: A comprehensive review
W.van LeeuwenN.de KeyserC
